Sleep Bruxism Treatment Market By Treatment Type (Dental Appliances, Botulinum Toxin Injections, Pharmacological Therapies, Behavioral Therapies, Physical Therapies), By Dental Appliance Type (Custom Stabilization Splints/Night Guards, Mandibular Advancement Devices, Over-the-Counter Mouth Guards, Digitally Manufactured Night Guards), By End User (Dental Clinics, Hospitals and Sleep Centers, Specialty Clinics, Physiotherapy and Behavioral Care Centers, Homecare Settings), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Sleeping Bruxism Treatment Market: From Nighttime Grinding to a Growing Preventive-Care Economy

The Global Sleep Bruxism Treatment Market was valued at USD 590 million in 2025 and is projected to reach USD 923 million by 2032, expanding at a CAGR of 6.6% during 2026–2032, according to internal projections by Strategic Market Research.

 

Sleep bruxism (teeth grinding) has no single cure, but treatment focuses on protecting your teeth from wear and relaxing your jaw. Standard approaches include custom-fitted dental mouth guards, stress reduction, and lifestyle changes like limiting caffeine and alcohol. Sleep bruxism treatment also relies on physical therapy, lifestyle changes such as limiting caffeine and alcohol, and selected medical options for severe jaw pain. Overall, treatment mainly aims to protect the teeth from wear, relax strained jaw muscles, reduce pain, and manage the sleep, stress, or medication-related factors associated with repeated nighttime grinding.

 

A Device-Led Market with a Wider Care Team Behind It

Sleeping bruxism treatment is primarily device-led and clinician-guided. The main demand unit is a protective oral appliance, particularly a custom stabilization splint or night guard. The core buyer is the patient, while dentists, dental laboratories, orthodontic practices, sleep specialists, physiotherapists, and selected medical practitioners influence product choice and repeat treatment.

Dental appliances generated approximately 61% of market revenue in 2025, or about USD 360 million. Behavioral and physical therapies represented about 22%, equivalent to nearly USD 130 million, while medicines and injections accounted for 17%, or approximately USD 100 million. Dental clinics captured nearly 69% of total spending, representing about USD 407 million, because diagnosis, fitting, adjustments, and long-term monitoring are commonly handled through dental practices.

 

A Large Undiagnosed Population and a Much Smaller Treated Patient Base

A 2024 systematic review and meta-analysis estimated the global prevalence of sleep bruxism at 21%. The estimate rose to 43% when studies used overnight sleep-lab monitoring rather than patient-reported symptoms. North America recorded the highest regional estimate at 31%, followed by South America at 23%, Europe at 21%, and Asia at 19%. The review examined 176 study populations, including 97 adult-focused studies and 79 studies involving minors, but also identified wide variation between diagnostic methods and locations.

Prevalence generally falls with age. Sleep bruxism is estimated to affect approximately 15% of adolescents, declining to around 8% of middle-aged adults and 3% of older adults. Younger patients therefore form an important long-term customer base, although treatment decisions for children are more cautious because many eventually outgrow the condition.

The U.S. Census Bureau estimated that the national population reached 340.1 million in 2024, an increase of 0.98% from 336.8 million in 2023, expanding the underlying population exposed to sleep, stress, and oral-health conditions. The CDC reported that 65.5% of U.S. adults aged 18 and older received a dental examination or cleaning during 2023, giving dentists a broad opportunity to detect tooth wear or jaw symptoms during routine visits.

Strongest treatment triggers are visible tooth wear, fractured fillings or crowns, tooth sensitivity, jaw stiffness, temple headaches, and pain around the jaw joint. Regular dental examinations remain an important entry point. NIDCR states that severe bruxism can cause damaged teeth, jaw pain, muscle tiredness, and headaches, while regular dental care supports earlier identification of these signs.

 

First-Line Treatment: Protecting Teeth Without Stopping the Grinding Behavior

Custom stabilization splints remain the commercial center of the market. These guards separate the upper and lower teeth and absorb or redirect damaging pressure, protecting natural teeth, crowns, veneers, implants, and other restorations from repeated nighttime loading.

Mayo Clinic and the National Institute of Dental and Craniofacial Research identify splints and mouth guards as common management tools. However, clinical evidence and commercial messaging must distinguish between protecting the teeth and eliminating the grinding behavior. A night guard may prevent direct tooth-to-tooth contact without removing the underlying urge to clench. NIDCR lists mouth guards among four principal management routes alongside behavior change, stress management, and repair of damaged teeth.

Products emphasizing protection, fit, comfort, durability, and ease of replacement align more closely with available evidence. Clinical assessments indicate that guards can prevent dental damage and reduce grinding noise, although their effect on nighttime jaw activity may be temporary.

Custom guards hold the premium end because they are shaped to the patient’s bite and usually involve dental consultation, laboratory work, or digital design. Over-the-counter guards compete through affordability and immediate availability. DenTek offers ready-to-wear and heat-fitted guards, while Glidewell supplies custom laboratory-made and digitally printed bite splints.

Strategic Market Research estimate that custom stabilization splints represented approximately 46% of the total market in 2025, equivalent to nearly USD 271 million and roughly 75% of the dental-appliance segment. Other oral appliances, including mandibular advancement devices and lower-priced retail or direct-to-consumer guards, collectively accounted for about 15% of the market, or approximately USD 89 million.

 

When Breathing and Grinding Share the Same Night

The relationship between sleep bruxism and obstructive sleep apnea is creating a more specialized treatment pathway. Patients who grind their teeth while also snoring, gasping, waking repeatedly, or experiencing daytime sleepiness may need sleep assessment rather than a routine protective guard alone.

Mandibular advancement devices become relevant when airway obstruction is confirmed. These appliances move the lower jaw and tongue slightly forward to maintain airflow. By reducing breathing interruptions and related sleep disturbances, they may also lower grinding episodes in selected patients. These products form part of the approximately USD 89 million non-custom-splint oral-appliance opportunity, alongside over-the-counter and direct-to-consumer guards.

CMS states that qualifying oral appliances used to treat diagnosed obstructive sleep apnea may be covered under the Medicare durable medical equipment benefit. Appliances used only for dental conditions, jaw-joint problems, or snoring without diagnosed sleep apnea are generally excluded.

CMS applies four coverage conditions to custom-fabricated mandibular advancement devices billed under code E0486. Its policy also treats the first 90 days as the normal fitting and adjustment period; appliances requiring continuing modification beyond that period may not qualify as durable medical equipment. This encourages suppliers and dental practices to prioritize accurate fitting, documentation, and coordination with the physician who confirms the sleep-apnea diagnosis.

 

What Each Treatment Does—and Its Clinical Limitations

The Sleep Bruxism Treatment Market includes established dental devices alongside a smaller group of medicines and injections used in selected cases. Some approaches protect the teeth, some improve nighttime breathing, and others reduce the strength of jaw-muscle contractions. None currently provides a universal cure.

The FDA has cleared several sleep bruxism devices through the 510(k) pathway, including LuxCreo Dental Night Guard Resin (Jan 2024), Slow Wave DS8 (Jun 2024), LIJIA Night Guard (Aug 2024), and Remi Custom Night Guard (Feb 2025). These clearances confirm ongoing innovation in prescription guards and digital oral appliances, not a cure for bruxism.

Occlusal splints, commonly called night guards, remain the main protective treatment. They create a physical barrier between the teeth, spread grinding pressure more evenly, and protect enamel and dental restorations. They may reduce strain around the jaw joint but do not stop the sleep-related signals that cause the jaw muscles to contract. Their commercial value comes from preventing damage rather than eliminating the underlying condition. FDA documentation for the Slow Wave DS8 states that the personalized appliance separates the upper and lower teeth to protect against grinding and clenching forces, with digital scans used to create a patient-specific fit.

Mandibular advancement devices serve a more specialized patient group. They gently move the lower jaw and tongue forward, helping keep the upper airway open during sleep. They are particularly relevant when sleep bruxism occurs alongside obstructive sleep apnea or repeated breathing-related sleep interruptions, but they should not be positioned as a routine replacement for every protective night guard.

Botulinum toxin injections are an off-label option for severe jaw pain or excessive muscle force. The treatment temporarily limits the signal that makes the jaw muscles contract, reducing muscle activity, grinding force, and pain without necessarily reducing the number of nighttime grinding episodes. The effect generally lasts for several months, creating repeat-treatment revenue, but bruxism is not included among the approved U.S. indications for BOTOX.

The FDA prescribing information records BOTOX’s initial U.S. approval in 1989 and lists nine approved indication groups, including chronic migraine, spasticity, cervical dystonia, and selected bladder, sweating, and eye conditions. Sleep bruxism is not among these indications, confirming that its use for nighttime grinding remains off-label rather than an FDA-approved bruxism treatment.

Clonazepam and clonidine have produced measurable reductions in small sleep studies, but neither represents a standard long-term treatment. One clinical review reported a reduction of approximately 42% in the sleep-bruxism index with clonazepam, while another study found that clonidine reduced bruxism activity by about 61%. Sedation, dependency concerns, blood-pressure effects, and limited study sizes restrict widespread use.

Gabapentin and tiagabine remain early-stage, off-label approaches. A small gabapentin study reported lower jaw-muscle activity and improved sleep quality, with results broadly comparable to stabilization-splint treatment after two months. Evidence for tiagabine is much weaker, so it remains an investigational possibility rather than a proven commercial treatment.

The government evidence therefore reinforces a divided market: FDA-cleared prescription mouthguards and oral appliances form the established device route, while botulinum toxin, clonazepam, clonidine, gabapentin, and tiagabine remain off-label or investigational for sleep bruxism. Medicines and injections represented approximately 17% of the market, or USD 100 million, in 2025. This medical-intervention segment is projected to grow at around 8.0% through 2032, outpacing the overall market CAGR of 6.6%, although dental appliances are expected to continue as the primary treatment approach.

 

Behavioral and Physical Therapies as an Adjunct Care Layer to Night Guards

Behavioral care, stress management, and physical therapy expand the market beyond appliances. NIDCR recommends relaxation activities, counseling where appropriate, reducing caffeine and alcohol consumption, and avoiding tobacco. Mayo Clinic also identifies stress management, behavior change, jaw-relaxation exercises, and biofeedback as possible parts of care. The NIDCR guidance, last reviewed in March 2025, also identifies alcohol, caffeine, smoking, stress, genetics, and selected medicines as factors that may contribute to bruxism.

Behavioral care, stress management, and physical therapy accounted for approximately 22% of total market revenue in 2025, equal to nearly USD 130 million. The revenue pool is fragmented across counseling, physiotherapy, pain management, wellness programs, and digital monitoring. Adoption is rarely structured as a single standardized treatment package, but integration with dental protection can improve adherence.

 

From Dental Labs to Real-Time Night Guards: The Digital Shift

Digital scanning and 3D printing are changing the economics of custom night guards. FDA documentation for the prescription Remi Custom Night Guard states that the appliance is intended to protect teeth and restorations against grinding and clenching. FDA issued its substantial-equivalence decision on February 10, 2025, after receiving the filing on November 13, 2024.

Formlabs announced in 2024 that two of its medical-grade dental resins had received FDA 510(k) clearance for directly printing prescription mouth guards, night guards, and bite splints. The company offers flexible and rigid materials to address different comfort and durability requirements.

Formlabs states that its Form 4B platform can produce up to eight splints or night guards in approximately 35 minutes. SprintRay reports output of up to eight full-arch appliances in under 45 minutes and an estimated material cost of around USD 3 per guard. These are manufacturer claims rather than total delivered treatment costs, but they illustrate the economics supporting digital adoption.

Faster turnaround allows practices to deliver appliances sooner, remake lost or damaged guards from stored digital files, reduce impression handling, and support same-day or next-day service models. Digital manufacturing directly addresses the custom stabilization-splint segment, which represented approximately 46% of the total market and USD 271 million in 2025, making it the largest immediate revenue pool for printable materials, scanners, design software, and dental-production platforms.

Competition spans dental laboratories, printer manufacturers, resin suppliers, direct-to-consumer brands, and retail oral-care companies. Relevant participants include Glidewell, Formlabs, SprintRay, Keystone Industries, Remi, and DenTek.

 

North America Leads Today; Asia-Pacific Has the Faster Runway

Strategic Market Research estimates that North America accounted for approximately 42% of global revenue in 2025, equal to about USD 248 million. High reported prevalence, a large dental workforce, direct-to-consumer availability, and early adoption of digital dentistry support regional leadership. The region is expected to expand at approximately 6.1% annually through 2032, slightly below the global CAGR of 6.6%.

Europe represented an estimated 27% of the market, or about USD 159 million in 2025, supported by established dental-care networks and growing use of digitally manufactured appliances.

Asia-Pacific held approximately 24%, equivalent to USD 142 million, and is projected to record the fastest regional CAGR of about 7.5%. Expanding urban dental networks, higher spending on restorative dentistry, improved awareness of sleep disorders, and access to lower-cost digital manufacturing support this acceleration.

North America, Europe, and Asia-Pacific together represented approximately 93% of global market revenue in 2025, or about USD 549 million. The remaining regions accounted for nearly 7%, equivalent to approximately USD 41 million.

 

Market Outlook:

Growth from USD 590 million in 2025 to USD 923 million by 2032 represents an absolute increase of approximately USD 333 million, or about 56.4%. This expansion will be driven by earlier diagnosis in dental settings, steady replacement demand for oral appliances, growing overlap with sleep-apnea management, and the adoption of lower-cost digital customization technologies. However, the market will continue to face structural constraints, including widespread underdiagnosis, uneven insurance reimbursement, inconsistent patient adherence, and the lack of a definitive pharmacological cure.

 

Sleep Bruxism Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 590 Million
Revenue Forecast in 2032	USD 923 Million
Overall Growth Rate	CAGR of 6.6% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Treatment Type, By Dental Appliance Type, By End User, By Geography
By Treatment Type	Dental Appliances, Botulinum Toxin Injections, Pharmacological Therapies, Behavioral Therapies, Physical Therapies
By Dental Appliance Type	Custom Stabilization Splints/Night Guards, Mandibular Advancement Devices, Over-the-Counter Mouth Guards, Digitally Manufactured Night Guards
By End User	Dental Clinics, Hospitals and Sleep Centers, Specialty Clinics, Physiotherapy and Behavioral Care Centers, Homecare Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Earlier detection of tooth wear and jaw symptoms during routine dental examinations; recurring replacement demand for custom night guards and stabilization splints; growing clinical overlap between sleep bruxism and obstructive sleep apnea; wider adoption of digital scanning and 3D-printed oral appliances; rising use of adjunct behavioral, physical, and pain-management therapies
Customization Option	Available upon request